DFTX
Definium Therapeutics, Inc.
NASDAQ: DFTX · HEALTHCARE · BIOTECHNOLOGY
$21.40
-2.95% today
Updated 2026-05-11
Market cap
$2.40B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.50
Dividend yield
—
52W range
$6 – $26
Volume
1.9M
Definium Therapeutics, Inc. (DFTX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-46559.00 | $-26636.00 | $-665984.00 | $-722451.00 | $-208119.00 | $-23.60M | $-45.82M | $-50.14M | $-64.36M | $-79.13M | $-131.56M |
| Capital expenditures | $0.00 | $30098.00 | $2.15M | $1.04M | $313457.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | — | — | — | $7.41M | $42.72M | $13.71M | $15.49M | $16.91M | $20.10M |
| Free cash flow | $-46559.00 | $-56734.00 | $-2.82M | $-1.77M | $-521576.00 | $-23.60M | $-45.82M | $-50.14M | $-64.36M | $-79.13M | $-131.56M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — |